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2002), and after the exclusivity period (February–August
2002) was: $1.89, $1.91, and $1.97 respectively, using an
assumed percentage rebate. Similarly, average estimated
payment per unit (post-rebate) for ﬂuoxetine 20mg 
capsules (generic) in the 2 latter periods was: $1.96 and
$0.79 respectively. Additional payments related to 
cost-savings not realized were estimated to be
$1,772,677. CONCLUSIONS: Regulations that limit
competition within the generic marketplace immediately
following branded patent-expiration may result in lost
opportunities for savings within publicly-ﬁnanced pre-
scription programs.
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OBJECTIVES: The overall purpose of this study was 
to determine West Virginia (WV) physicians’ attitude
toward cost-containment strategies and generic prescrib-
ing, and to assess their level of awareness and receptivity
towards academic detailing. METHODS: The top 2000
physicians by prescribing volume in the WV state employ-
ees health insurance program were surveyed using a 
self-administered mail questionnaire. Physician attitudes
toward popular pharmaceutical cost-control strategies
(formulary, prior-authorization, co-pays, generic and
therapeutic substitution, and incentives for formulary
adherence), generic prescribing, and the potential of 
academic detailing for appropriate and cost-effective
pharmaceutical use was assessed using Likert-type 
7-point scales. Generic prescribing frequency and patient
acceptance/inquiry for generic drugs and the preferred
format of academic detailing visits were also obtained.
RESULTS: A total of 455 (23%) usable responses were
obtained after 2 mailings. On a scale of 1 to 7 (highly
inappropriate to highly appropriate), generic substitu-
tion, increased patient co-pays for branded drugs, and
therapeutic substitution had the highest mean appro-
priateness scores of 5.30 (+1.68), 4.49 (+1.71), and
4.36(+2.01), respectively. All other strategies were 
considered inappropriate with incentives to physicians 
for prescribing from formularies considered the most
inappropriate. Physicians were neutral to mildly positive
toward generic drug prescribing, and reported a mean
proportion of 46% generic prescriptions written and a
78% patient acceptance of generic prescriptions when
written. Physicians were generally aware of academic
detailing and mildly positive about it with 69% of 
surveyed physicians expressing willingness to meet with
academic detailers. A once-a-month frequency of visit and
up to 20 minutes per visit was favored by almost half of
those physicians interested in academic detailing. CON-
CLUSIONS: Overall, WV physicians are less supportive
of cost-control strategies that impose restrictions on their
prescribing and more supportive of strategies that do not
impose on their prescribing. Study results indicate that
WV physicians are receptive to academic detailing.
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OBJECTIVES: To estimate the difference in respon-
siveness to drug beneﬁt changes between sick and 
healthy populations under different drug beneﬁt plans.
METHODS: Prescription spending in 2001, demo-
graphic, co-pays and chronic condition information of
107,710 primary participants between ages 18 to 64 was
obtained from Caremark PBM claims system. Existence
of chronic conditions identiﬁed through pharmacy claims
utilization algorithms was used as a proxy for sick people.
A 2-part model was used to estimate the prescription
spending on copay changes. The ﬁrst part used a logistic
regression to estimate the probability of incurring of any
prescription. The second part used an OLS regression 
on log of total spending for the utilizing participants.
RESULTS: Under a 1-Tier copay plan, if the co-pays
increase from $5 to $10, the reduction of total spending
is 6.4% more for sick people than for healthy people.
Under a 2-Tier plan, if the co-pays increase from $5 to
$10 for generic and $10 to $15 for brand, the reduction
of total spending is 10.2% more for sick people than 
for healthy people. Under a 3-Tier plan, if the co-pays
increase from $5 to $10 for generic, $10 to $15 for brand
formulary and $15 to $20 for brand non-formulary, the
reduction of total spending is 10.4% more for sick people
than for healthy people. CONCLUSIONS: Based on the
speciﬁc data set, this research shows that sick people 
are more responsive to drug beneﬁt changes. Since cost-
sharing designs are frequently used to contain total drug
spending, understanding drug beneﬁt designs for hetero-
geneous populations is crucial to achieve the optimal
balance of sponsor savings and participants’ health.
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OBJECTIVE: To retrospectively assess the impact of par-
ticipant cost-share levels on medication compliance rates
